[SCHEDULE 13G/A] AXON ENTERPRISE, INC. Amended Passive Investment Disclosure
Rhea-AI Filing Summary
Axon Enterprise Inc — The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Axon common stock. The filing explains that, in accordance with SEC Release No. 34-39538 (January 12, 1998), certain Vanguard subsidiaries and business divisions will report beneficial ownership separately following an internal realignment on January 12, 2026. The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports no beneficial ownership of Axon after internal realignment.
The filing states that The Vanguard Group now holds 0 shares (0%) of Axon common stock as reported in Amendment No. 12 to Schedule 13G/A. It attributes the change to an internal realignment and disaggregation of reporting among subsidiaries, citing SEC Release No. 34-39538 (January 12, 1998).
Practical implications depend on the separate reports filed by Vanguard’s subsidiaries; subsequent filings will show any redistributed holdings. Cash‑flow treatment and which entities (if any) now hold Axon shares are not detailed in this excerpt.
This is a reporting and organizational update, not a transaction signal.
The amendment explains a change in reporting structure—Vanguard disaggregated beneficial ownership so that subsidiaries report separately. The filing explicitly states the subsidiaries pursue the same investment strategies and that The Vanguard Group, Inc. "no longer has, or is deemed to have, beneficial ownership" over those securities.
Governance watchers should track the separate 13G/A entries from Vanguard entities to see any actual shifts in disclosed ownership levels; timing and amounts are to be read from those successor filings.